Market: The Emerging Prospects of Muscle Spasticity Therapeutics

Muscle Spasticity Market 




The Muscle Spasticity Therapeutics Market is estimated to be valued at US$ 4,167.6 million in 2023 and is expected to exhibit a CAGR of 8.9% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:


Muscle spasticity refers to stiffening or tightening of the muscles which occurs as a result of damage to the parts of the brain or spinal cord that control voluntary movement. It is commonly seen in conditions such as cerebral palsy, multiple sclerosis and spinal cord injuries. Several drugs and treatments are available to manage the symptoms of muscle spasticity including botulinum toxins, baclofen, dantrolene sodium and cannabinoids.


Market Dynamics:


The key drivers boosting growth of the muscle spasticity therapeutics market include rising prevalence of neurological disorders associated with muscle spasticity and increasing research & development activities. According to WHO, around 50 million people worldwide are suffering from epilepsy, while over 40 million have stroke-related disabilities. The prevalence of multiple sclerosis has also increased over the past few decades. In addition, there has been considerable innovation in drugs and treatment approaches for muscle spasticity such as development of novel botulinum toxin formulations with longer duration of action and targeted delivery to spastic muscles.

 

Market key trends:


One of the key trends in the muscle spasticity market is the rising prevalence of neurological disorders globally. The increasing number of patients suffering from conditions like multiple sclerosis, cerebral palsy, spinal cord injuries, and stroke is expected to drive the demand for effective treatment of muscle spasticity. As per estimates, over 2.5 million people in the U.S. alone suffer from multiple sclerosis, which is one of the leading causes of muscle spasticity.


SWOT Analysis


Strength: The muscle spasticity market benefits from the availability of advanced treatment options like botulinum toxin injections and antispasticity medication.
Weakness: High treatment costs associated with intrathecal baclofen therapy and surgical interventions can limit their adoption rate.
Opportunity: Development of novel drug formulations, gene therapies, and stem cell-based treatments can present new growth opportunities.
Threats: Stringent regulations for approval of new drugs and high failure rates during clinical trials are major challenges.


Key Takeaways


The Global Muscle Spasticity Market Size was valued at US$ 4,167.6 million in 2023 and is expected to witness high growth, exhibiting a CAGR of 8.9% over the forecast period. The rising incidence of neurological disorders globally is a key driver for market growth.

Regional analysis
North America dominated the global market in 2023 and is expected to remain the fastest growing region during the forecast period. This can be attributed to the growing multiple sclerosis patient pool in the US and Canada and high adoption of advanced treatment approaches. Asia Pacific is anticipated to witness the highest CAGR owing to increasing healthcare expenditures and awareness regarding muscle spasticity management in China and India.

Key players
Key players operating in the muscle spasticity market are Ipsen Pharma, Allergan, Acorda Therapeutics, Inc., Merz Pharma, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Ltd., Johnson & Johnson Private Limited, Zydus Cadila, F. Hoffmann-La Roche Ltd., and Elite Pharmaceuticals Inc. The market is competitive in nature with these major players adopting strategies like partnerships, collaborations and new product launches.



Read More - https://www.insightprobing.com/muscle-spasticity-market-share-trends-and-analysis-demand/



 

Comments

Post a Comment

Popular posts from this blog

Riding the Wave: Navigating Dynamics in the Windsurf Foil Board Market

Image
   Windsurf Foil Board Market In the exhilarating world of water sports, the Windsurf Foil Board Market emerges as a key player, offering enthusiasts innovative equipment to enhance their riding experience. As this niche market continues to gain traction among windsurfing aficionados worldwide, it undergoes significant shifts influenced by various drivers, challenges, and geographical nuances. The Windsurf Foil Board Market size was valued at  US$ 167.4 Mn in 2024  and is expected to reach  US$ 268.6 Mn by 2031 , growing at a compound annual growth rate  (CAGR) of 7% from 2024 to 2031 Key Takeaways A prominent trend in the Windsurf Foil Board Market Demand is the increasing adoption of foil technology. Foil boards, equipped with hydrofoils beneath the waterline, enable riders to glide effortlessly above the water's surface, providing a thrilling and dynamic experience. This technological innovation has revolutionized the windsurfing landscape, attrac...
Read more

Idiopathic Hypersomnia Treatment Market is Anticipated to Witness High Growth Owing to Increasing Prevalence of Idiopathic Hypersomnia

Image
  Idiopathic Hypersomnia Treatment Market Idiopathic hypersomnia is a neurological sleep disorder characterized by excessive daytime sleepiness and long periods of sleep that does not improve even after long sleep. The treatment of idiopathic hypersomnia is done through medication and behavioral therapies. Medications like psychostimulants, serotonin modulators, wakefulness promoting agents are used to treat the condition and increase wakefulness. The increasing prevalence of idiopathic hypersomnia due to genetic and environmental factors is expected to drive the growth of the idiopathic hypersomnia treatment market. The Global Idiopathic Hypersomnia Treatment Market is estimated to be valued at US$ 389.86 Mn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 to 2030. Key Takeaways Key players operating in the Idiopathic Hypersomnia Treatment Market are Esaote SPA, Epica Animal Health, IDEXX Laboratories, Carestream Health, IMV Imaging, Fujifilm Hold...
Read more

Navigating Opportunities In The Niemann-Pick Disease Drug Type C Treatment Market

Image
  Niemann-Pick Disease Drug Type C Treatment Market Key Takeaways The Niemann-Pick Disease Drug Type C Treatment Market is witnessing significant growth, driven by advancements in medical research and a deeper understanding of the disease pathology. Niemann-Pick Disease Type C (NPC) is a rare genetic disorder characterized by the accumulation of cholesterol and other lipids within cells, leading to progressive neurological and visceral symptoms. With an increasing focus on rare diseases and orphan drug development, the market for NPC treatment is expanding rapidly, offering hope to patients and caregivers. Key players in the pharmaceutical industry are actively investing in research and development to bring novel therapies to market, underscoring the potential for transformative interventions in NPC management. Global Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at  US$ 45.40  million  in 2024, and is expected to exhibit a  CAG...
Read more